How a payload is attached to an antibody determines how uniform - and how well-behaved - the resulting drug is. US12318457B2 - "Oligosaccharide linker, linker-payload comprising the same and glycan chain-remodeled antibody-drug conjugate," issued June 3, 2025 to GeneQuantum Healthcare (Suzhou) Co., Ltd. - claims attaching the payload through a remodeled glycan, at a defined site.
The load-bearing limitation is site-specific conjugation. Conventional conjugation attaches payloads at random surface residues (lysines or cysteines), producing a heterogeneous mixture with a variable drug-to-antibody ratio (DAR). The claimed method remodels the antibody's glycan - the sugar chain on its constant region - and attaches the payload there, at a controlled, defined site, yielding a homogeneous conjugate.
The CPC profile is conjugation chemistry specific to this approach: A61K 47/6889 (linker classes), A61K 47/549 (the oligosaccharide linker), A61K 47/65, and the A61K 47/680xx payload-attachment series. The recurring glycan-and-linker tags mark this as a site-specific conjugation claim, distinct from random-attachment chemistries.
Why does site-specificity decide scope and value? Because a homogeneous, defined-DAR conjugate has a more predictable therapeutic window and cleaner pharmacology than a random mixture - a real clinical advantage. The claim reaches the glycan-remodeling conjugation method specifically; a competitor using cysteine-engineering or other site-specific approaches may fall outside a claim drawn to glycan-based attachment.
For the landscape, site-specific conjugation is one of the most actively contested corners of the ADC estate, with multiple incompatible approaches - glycan remodeling, engineered cysteines, enzymatic tagging - each separately patented. Freedom-to-operate for a next-generation ADC means choosing a conjugation approach and clearing the specific estate around it; GeneQuantum's glycan-remodeling grant defines one of those approaches.